International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 4 July-August 2024 Submit your research before last 3 days of August to publish your research paper in the issue of July-August.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 4
July-August 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Temozolomide on Aggressive Pituitary Adenomas: About 4 Cases and Review of the Literature

Author(s) Esma Kerboua, Chahira Mazouzi, Radia Benyahia, L. Atroune, F.Terkmani
Country Algeria
Abstract Pituitary adenomas represent 15 to 20% of all brain tumors . They affect 1/1000 of the world population, some pituitary adenomas with high Ki-67 indexes exhibit aggressive behaviors, such as rapid growth, early and frequent recurrence, and resistance to conventional treatment, even in the absence of metastasis . Many trials have focused on the role of chemotherapy in the treatment of these aggressive and atypical adenomas The objective: Monitoring of patients on temozolomide . we report the follow-up of 4 patients (pts) of 10 pts treated in
our department during the period (2012-2019), 2 women / 2 men presenting an aggressive pituitary macro-adenoma, having benefited from excision surgery, radiotherapy and received medical treatment with temozolomide initiated with clinical, biological and radiological evaluation of the therapeutic response and search for p53 and ki 67 in the diagnosis. A clinical improvement was noted in our 4 pts; Radiologically: a partial response was obtained in 1pts, two stabilities and one progression . The average duration of treatment is 26 months (12 - 40) with manageable side effects .Temozolomide appears to be effective in the treatment of aggressive pituitary adenomas and may currently constitute a therapeutic alternative when all resources are exhausted, thus allowing control of the disease.
Keywords Pituitary adenomas , agressive tumors ,temozolomide
Field Medical / Pharmacy
Published In Volume 6, Issue 2, March-April 2024
Published On 2024-04-27
Cite This Temozolomide on Aggressive Pituitary Adenomas: About 4 Cases and Review of the Literature - Esma Kerboua, Chahira Mazouzi, Radia Benyahia, L. Atroune, F.Terkmani - IJFMR Volume 6, Issue 2, March-April 2024. DOI 10.36948/ijfmr.2024.v06i02.17600
DOI https://doi.org/10.36948/ijfmr.2024.v06i02.17600
Short DOI https://doi.org/gtsg8s
View / Download PDF File

Share this


E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com